{"id":10949,"date":"2020-01-09T16:40:36","date_gmt":"2020-01-09T15:40:36","guid":{"rendered":"https:\/\/udic.es\/?p=10949"},"modified":"2020-01-09T16:40:36","modified_gmt":"2020-01-09T15:40:36","slug":"an-amazing-phase-i-trial-in-parkinson","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/an-amazing-phase-i-trial-in-parkinson\/","title":{"rendered":"An amazing Phase I trial in Parkinson"},"content":{"rendered":"
We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.<\/p>\n","protected":false},"excerpt":{"rendered":"
We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.<\/p>\n","protected":false},"author":4,"featured_media":9279,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"class_list":["post-10949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-parkinson-en"],"yoast_head":"\n